
Novo Nordisk, the alchemists behind Ozempic, were first to market with these hormonal tinkerings back in 2017, and enjoyed a comfortable lead for a time. But the market, as any seasoned goblin trader will tell you, is a fickle beast. Recently, another player has swaggered onto the scene, rather like a particularly well-fed troll demanding a larger share of the bridge toll. So, if you’re an investor seeking a champion in this particular gold rush – and let’s be honest, who isn’t? – it might be prudent to forget about Ozempic. The real action, it appears, is with a different giant entirely.